CA2522379 THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Office Canada

Application Number 2522379

Application Date 09.04.2004

Publication Number 2522379

Publication Date 28.10.2004

Grant Number

Grant Date 23.10.2012

Publication Kind C

IPC

View more classifications

View less classifications

CPC

View more classifications

View less classifications

Applicants CHIRON CORPORATION

Inventors RAPPUOLI, RINO
MASIGNANI, VEGA
STADLER, KONRAD
GREGERSEN, JENS-PETER
CHIEN, DAVID
HAN, JANG
POLO, JOHN
WEINER, AMY
HOUGHTON, MICHAEL
SONG, HYUN CHUL
SEO, MI YOUNG
DONNELLY, JOHN J.
KLENK, HANS DIETER
VALIANTE, NICHOLAS

Priority Data 60/462,218 10.04.2003 US
60/462,418 12.04.2003 US
60/462,465 11.04.2003 US
60/462,748 13.04.2003 US
60/463,109 14.04.2003 US
60/463,460 15.04.2003 US
60/463,668 16.04.2003 US
60/463,971 18.04.2003 US
60/463,983 17.04.2003 US
60/464,838 22.04.2003 US
60/464,899 22.04.2003 US
60/465,273 23.04.2003 US
60/465,535 24.04.2003 US
60/468,312 05.05.2003 US
60/473,144 22.05.2003 US
60/495,024 14.08.2003 US
60/505,652 23.09.2003 US
60/510,781 11.10.2003 US
60/529,464 11.12.2003 US
60/536,177 12.01.2004 US
60/560,757 07.04.2004 US

Title

(EN) THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS

(FR) LE CORONAVIRUS DU SYNDROME RESPIRATOIRE AIGU GRAVE

Abstract

(EN)

An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.

Also published as

EP1618127

CN1829736

ES2529736

AU2004230485

WO/2004/092360

US20060257852

JP2006510100

NZ543467

AU2009201478

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology
11	DNA or RNA fragments; Modified forms thereof
31	Genes encoding microbial proteins, e.g. enterotoxins
33	Genes encoding viral proteins
40	Proteins from RNA viruses, e.g. flaviviruses
50	Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
70	Carbohydrates; Sugars; Derivatives thereof

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35	Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66	Microorganisms or materials therefrom
76	Viruses; Subviral particles; Bacteriophages

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38	Medicinal preparations containing peptides
16	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. CA2522379 - THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS

WIPO Translate

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
H	SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21	Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
14	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005	from viruses
08	RNA viruses
165	Coronaviridae, e.g. avian infectious bronchitis virus

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q	MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1	Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
25	involving enzymes not classifiable in groups C12Q1/26-C12Q1/7097

G	PHYSICS
01	MEASURING; TESTING
N	INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33	Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48	Biological material, e.g. blood, urine; Haemocytometers
50	Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53	Immunoassay; Biospecific binding assay; Materials therefor
569	for microorganisms, e.g. protozoa, bacteria, viruses